A Study of LY3867070 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

196 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-27

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY2886721 in Healthy Participants

NCT01534273

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3084077 in Healthy Participants

NCT01846702

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3537031 in Healthy Participants

NCT04648865

Healthy

COMPLETED PHASE1

A Study of LY3540378 in Healthy Participants

NCT04768855

Healthy

COMPLETED PHASE1

A Study of LY3848575 in Healthy Participants

NCT05727072

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parts A, B, and C are parallel. Part D is open-label fixed-sequence. Part E is crossover.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Part D will be open-label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3867070 (Part A)

Single-Ascending Dose of LY3867070 administered orally

Group Type EXPERIMENTAL

LY3867070

Intervention Type DRUG

Administered orally

LY3867070 (Part B)

Multiple-Ascending Doses of LY3867070 administered orally

Group Type EXPERIMENTAL

LY3867070

Intervention Type DRUG

Administered orally

LY3867070 (Part C)

Multiple Doses of LY3867070 administered orally

Group Type EXPERIMENTAL

LY3867070

Intervention Type DRUG

Administered orally

Placebo (Parts A-C)

Placebo administered orally

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally

LY3867070 (Part D)

Drug-Drug Interaction (DDI) administered orally

Group Type EXPERIMENTAL

LY3867070

Intervention Type DRUG

Administered orally

LY3867070 (Optional Part E)

LY3867070 administered orally

Group Type EXPERIMENTAL

LY3867070

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3867070

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are overtly healthy as determined by medical evaluation
* Part C of the study includes only Japanese and Chinese participants
* Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive

Exclusion Criteria

* Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy
* Have a significant history or current thyroid disease
* Have a significant history of or current psychiatric disorders, rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome and hyperaldosteronism), hematological, or neurological disorders
* Are smokers (including electronic cigarettes) within 6 months prior to screening and unwilling to refrain from smoking for the duration of the study.
* Unwilling to undergo skin biopsies (for Part B only)
* Are unwilling to have body hair cut or shaved in cases where hair, in the investigator's opinion, could interfere with noninvasive skin patch

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes